

Date: 8th August, 2024

To,
The Manager,
Department of Corporate Services,
BSE Limited
P. J. Towers, Dalal Street,
Fort, Mumbai – 400 001
Scrip Code: 533573

To,
The Manager,
Listing Department,
National Stock Exchange of India Ltd.
'Exchange Plaza', Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051
NSE Symbol: APLLTD

Dear Sir/Madam,

Sub: Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2024.

With reference to the captioned subject, please find enclosed herewith Press Release on the Unaudited Financial Results for the quarter ended 30th June, 2024.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

Manisha Saraf
Company Secretary

Encl.: A/a.

ALEMBIC PHARMACEUTICALS LIMITED

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229
Website : www.alembicpharmaceuticals.com • E-mail : alembic@alembic.co.in • CIN : L24230GJ2010PLC061123

Press Release
PBT up 21% to Rs. 157 Crores for the Quarter

Vadodara, August 8th, 2024

Alembic Pharmaceuticals Limited reported its consolidated financial results for the first quarter ended 30th June, 2024.

Financial Highlights

For the Quarter

- Net Sales increased 5% to Rs.1562 crores.
- Net Profit up 12% to Rs.135 crores.
- EBITDA up 14% to Rs. 239 crores.

Mr. Shaunak Amin, MD, Alembic Pharmaceuticals Limited said “India Branded Business continues to work on improving the execution ability both in quality & scale. The Specialty and Animal health segment witnessed robust growth.

The USFDA conducted an audit at our Formulation facility F1, without any observations, underscoring our dedication to compliance and quality. The US business grew by 18% during the quarter”

Operational Highlights

India Branded Business

- India Branded Business grew 9% to Rs. 572 crores for the quarter.
- Recorded robust growths in specialty therapies like Gynecology, Gastrointestinal, Anti Diabetic and Ophthalmology therapies and performed relatively better than the market in acute therapies.
- Excess heat waves in Q1 FY 25 lead to unnatural market disturbances in affected geographies.
- Animal Health business grew 23% for the quarter with basket of strong brands driving outperformance.
- New launches continue to do well along with promising future launches across key segments.

International Business

- US Generics grew 18% to Rs. 461 crores for the quarter.
- 2 Launches in the US market during the quarter.
- Ex-US International Formulations grew 2% to Rs. 271 crores for the quarter.
- 206 Cumulative ANDA approvals.

API Business

- API business at Rs. 259 crores for the quarter.

The summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY25	Q1 FY24	% Change
Formulation			
India	572	524	9%
USA	461	390	18%
Ex- US	271	266	2%
API	259	305	(15%)
Total	1562	1486	5%

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a field force of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com;
(reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai

Phone: +91 022- 66953681 | 7045504460

Email: ajay.desai@alembic.co.in